Effects of AIT-082, a purine derivative, on tremor induced by arecoline or oxotremorine in mice

Pharmacology

Volumn 80, Issue 1, 2007, Pages 21-26

  Nannan, Gao ^a   Runmei, Yang ^a   Fusheng, Lin ^a   Shoulan, Zhang ^a   Guangqing, Lei ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

AIT 082; Parkinson's disease; Tremor

Indexed keywords

ARECOLINE; LETEPRINIM; OXOTREMORINE;

ANIMAL MODEL; ARTICLE; CHOLINERGIC RECEPTOR BLOCKING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG MEGADOSE; LOW DRUG DOSE; MALE; MOUSE; NERVE CELL STIMULATION; NONHUMAN; PRIORITY JOURNAL; TREMOR;

AMINOBENZOIC ACIDS; ANIMALS; ARECOLINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOXANTHINES; MALE; MICE; MICE, INBRED ICR; MUSCARINIC AGONISTS; OXOTREMORINE; TREMOR;

EID: 34347349027     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102601     Document Type: Article

References (24)

1. Chengwen L, Zeng L: The current situation and expectation of the treatment of Parkinson's disease with traditional Chinese medicine. J Hunan Coll Tradit Chinese Med 1998; 18:67.
2. Min Y, Hairong D, Xinsheng D: Recent advance in studies on etiopathogenesis and pathogenesis of Parkinson's disease. J Clin Neurol 2002;2:57-59.
3. Fei C, Xuebing C, Shenggang S, Yuanwu M, Tao W, Jixiang C, Etang D: Experimental research on the treatment of Parkinson's disease and its neurotoxicity with different doses of L -Dopa. Chin J Gerontol 2001;21:377.
4. Mochizuki H, Mori H, Mizuno Y: Apoptosis in neurodegenerative disorders. J Neural Transm 1997;50(suppl):125-140.
5. Glasky AJ, Melchior CL, Pirzadeh B, Heydari N, Ritzmann RF: Effect of AIT-082, a purine analog, on working memory in normal and aged mice. Pharmacol Biochem Behav 1994; 47:325-329.
6. Middlemiss PJ, Glasky AJ, Rathbone MP, et al: AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells. Neurosci Lett 1995;199:131-134.
7. Juurlink BHJ, Rathbone MP: The hypoxanthine derivative AIT-082 promotes neurite formation and regeneration in cultured hippocampal neurons. Soc Neurosci Abstr 1998; 24:1941.
8. Rathbone MP, Middlemiss PJ, Crocker C, et al: AIT-082 as a potential neuroprotective and regenerative agent in stroke and central nervous system injury. Exp Opin Invest Drugs 1999;8:1-8.
9. Middlemiss PJ, Imitiaz M, Jiang S, et al: The synthetic purine AIT-082 enhances recovery after acute spinal cord crush injury in rats. Soc Neurosci Abstr 1999;25:1002.
10. William JK: Techniques utilized in the evaluation of psychotropic drugs on animal activity. Pharm Sci 1966;55:995.
11. Schulte JW: Further study of central stimulation from sympathomimetic amines. J Pharmacol Exp Ther 1941;71:62.
12. Mizuno Y, Mori H, Kondo T: Parkinson's disease: from etiology to treatment. Intern Med 1995;34:1045.
13. Checkoway H, Nelson LM: Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 1999;10:327-336.
14. Finkelstein DI, Stanic D, Parish CL, et al: Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000;97:99-112.
15. Kingsbury AE, Marsden CD, Foster OJ: The vulnerability of nigral neural neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis an in situ hybridization study. Mov Disord 1999; 14:206-218.
16. Ruyi Z, Lin L, Houxi A, Cuifei Y: Effects of Jian-Xing on three animal models to mimic muscle tremors of Parkinson's disease. Chin J Rehabil Theory Pract 2004;10:38-40.
17. Taylor EM, Yan R, Hauptmann N, et al: AIT-082, a cognitive enhancer, is transported into brain by a nonsaturable influx mechanism and out of brain by a saturable efflux mechanism. J Pharmacol Exp Ther 2000; 293:813-821.
18. Yan R, Taylor EM: Neotrofin is transported out of brain by a saturable mechanism: possible involvement of multidrug resistance and monocarboxylic acid transporters. Drug Metab Dispos 2002;30:513-518.
19. Chu-LaGraff Q, Pham H, Taylor EM, et al: Effect of AIT-082 on brain NGF levels and transport of AIT-082 across the blood-brain barrier. Soc Neurosci Abstr 1998;24:1941.
20. Glasky MS, Conner JM, Tuszynski MH: Oral administration of AIT-082 stimulates BDNF and NGF expression in vivo in rats. Soc Neurosci Abstr 2001;27:137.10.
21. Feng L, Wang CY, Jiang H: Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons. Brain Res Mol Brain Res 1999;66:62-70.
22. Mogi M, Togari A, Kondo T, et al: Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 1999;270:45-48.
23. Parain K, Murer MG, Yan Q, et al: Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 1999;10:557-561.
24. Galpern WR, Frim DM, Tatter SB, et al: Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant 1996;5:225-232.